Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO

NCT06267729 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06267729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06267729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 12, 2024
Completion date
November 24, 2026
Enrollment
60 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer